- Home
- PIII vs ACXP Comparison
PIII vs ACXP Comparison
Compare PIII & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ACXP
- Stock Information
- Founded
- PIII 2015
- ACXP 2017
- Country
- PIII United States
- ACXP United States
- Employees
- PIII N/A
- ACXP N/A
- Industry
- PIII Medical/Nursing Services
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ACXP Health Care
- Exchange
- PIII Nasdaq
- ACXP Nasdaq
- Market Cap
- PIII 32.2M
- ACXP 31.4M
- IPO Year
- PIII N/A
- ACXP 2021
- Fundamental
- Price
- PIII $0.20
- ACXP $0.83
- Analyst Decision
- PIII Buy
- ACXP Strong Buy
- Analyst Count
- PIII 3
- ACXP 1
- Target Price
- PIII $2.38
- ACXP $12.00
- AVG Volume (30 Days)
- PIII 347.2K
- ACXP 248.6K
- Earning Date
- PIII 11-12-2024
- ACXP 11-12-2024
- Dividend Yield
- PIII N/A
- ACXP N/A
- EPS Growth
- PIII N/A
- ACXP N/A
- EPS
- PIII N/A
- ACXP N/A
- Revenue
- PIII $1,476,630,000.00
- ACXP N/A
- Revenue This Year
- PIII $21.45
- ACXP N/A
- Revenue Next Year
- PIII N/A
- ACXP N/A
- P/E Ratio
- PIII N/A
- ACXP N/A
- Revenue Growth
- PIII 25.38
- ACXP N/A
- 52 Week Low
- PIII $0.18
- ACXP $0.72
- 52 Week High
- PIII $1.78
- ACXP $5.28
- Technical
- Relative Strength Index (RSI)
- PIII 35.62
- ACXP 33.67
- Support Level
- PIII $0.22
- ACXP $0.72
- Resistance Level
- PIII $0.23
- ACXP $0.91
- Average True Range (ATR)
- PIII 0.02
- ACXP 0.11
- MACD
- PIII 0.00
- ACXP 0.02
- Stochastic Oscillator
- PIII 26.62
- ACXP 24.42
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.